• Nie Znaleziono Wyników

The Voice of the Editor-in-Chief

N/A
N/A
Protected

Academic year: 2022

Share "The Voice of the Editor-in-Chief"

Copied!
2
0
0

Pełen tekst

(1)

1

www.dk.viamedica.pl

the Society, with its own ISSN number, in order to address the needs of our readers in the country, translations from individual issues of the original journal will be issued in parallel as translated supplements of the whole issues of

“Clinical Diabetology”.

Our efforts aiming at substantial strengthening of the journal have not gone unnoticed since from the beginning of 2016 “Clinical Diabetology” gained 10 points in the ranking of journals of the Ministry of Science and Higher Education. Here I would like to thank the Via Medica publishing house, Main Board of the Polish Diabetes Society and all members and supporters of the Society, whose actions supported the previous and current Editor-in-Chief in achieving this undoubted success in a tangible way.

Enjoy the lecture

Prof. Janusz Gumprecht, MD, PhD Editor-in-Chief of „Clinical Diabetology”

We would like to present you the next issue of

“Diabetologia Kliniczna”, the issue that ends editorial year 2015, and at the same time the first issue, which appears in its entirety in English under the title CLINICAL DIABETOLOGY. This change is a result of systematic de- velopment of our journal aiming at further increasing its presence and importance on the international arena and striving to introduce “Clinical Diabetology” to the PubMed bibliographic base and ultimately to the list of scientific journals indexed in bibliographic databases, created by the ISI in Philadelphia termed as “Philadelphia list”. English version of the journal will appear in an originally electronic form, in an open access mode. At the same time, however, I would like to assure you that until the moment of crea- tion of the Polish version as a formally separate journal of

The Voice of the Editor-in-Chief

Dear Ladies and Gentlemen,

Colleagues,

(2)

Cytaty

Powiązane dokumenty

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with